Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B

Gut and Liver

Volumn 9, Issue 6, 2015, Pages 776-783

  Lee, Sangheun ^a   Park, Jun Yong ^b,c   Song, Kijun ^b   Kim, Do Young ^b,c   Kim, Beom Kyung ^b,c   Kim, Seung Up ^b,c   Ku, Hye Jin ^b   Han, Kwang Hyub ^b,c,d   Ahn, Sang Hoon ^b,c,d  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Liver Cirrhosis Clinical Research Centre   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Entecavir; Estimated glomerular filtration rate; Telbivudine

Indexed keywords

ENTECAVIR; TELBIVUDINE; ANTIVIRUS AGENT; GUANINE; THYMIDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; TREATMENT INDICATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; FIBROSIS; HEPATITIS B, CHRONIC; PATHOPHYSIOLOGY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; THYMIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946707905     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl14297     Document Type: Article

References (40)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373: 582-592.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
3. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26 Suppl 1:138-143.
4. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-754.
5. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
7. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19:93-95.
8. Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014;146:138-146.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
10. Cuddy ML. Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1). J Pract Nurs 2005;55:17-21.
11. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011;34 Suppl 1:S11-S61.
12. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 2011;18:892-896.
13. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-834.
14. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-734.
15. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-2006.
16. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005;11:1843-1847.
17. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66: 1153-1158.
18. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:941-946.
19. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
20. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
21. Kwon DH, Kim IH, Choung BS, et al. Continuous long-term entecavir therapy in naive chronic hepatitis B patients showing partial virologic response. Gut Liver 2013;7:712-718.
22. Kim MN, Kim SU, Kim BK, et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int 2014;34:1216-1223.
23. Kim MN, Kim SU, Park JY, et al. Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir. J Clin Gastroenterol 2014;48:272-278.
24. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
25. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444.
26. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
27. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
28. Park H, Park JY, Kim SU, et al. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013;19:7671-7679.
29. Ahn SH, Kweon YO, Paik SW, et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int 2012;6:696-706.
30. Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732-743.
31. Tsai MC, Lee CM, Chiu KW, et al. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother 2012;67:696-699.
32. Nishimura M, Kato Y, Tanaka T, et al. Significance of estimating the glomerular filtration rate for the management of hypertension in type 2 diabetes with microalbuminuria. Hypertens Res 2013;36:705-710.
33. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014;37 Suppl 1:S14-S80.
34. Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008;51:S13-S20.
35. Buckalew VM Jr, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996;28:811-821.
36. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005;31:1693-1699.
37. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-2077.
38. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
39. Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci 2011;56:977-987.
40. Liang KH, Chen YC, Hsu CW, Chang ML, Yeh CT. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon 2014;14:e15074.